| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1002/14651858.CD002966.PUB4 |
| P8608 | Fatcat ID | release_uwghkcefprdcvgfyfwkn4gbele |
| P698 | PubMed publication ID | 26421423 |
| P50 | author | David Moher | Q28036061 |
| Marta Roqué | Q28354251 | ||
| P2093 | author name string | Angel Mataix | |
| Antonio Saenz | |||
| Inmaculada Fernandez-Esteban | |||
| Monica Ausejo Segura | |||
| P2860 | cites work | Efficacy of metformin in the treatment of NIDDM. Meta-analysis | Q22241285 |
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| Metformin | Q22250907 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses | Q27860840 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. | Q54236486 | ||
| Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. | Q54243732 | ||
| Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet | Q55627545 | ||
| Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group | Q66972631 | ||
| Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus | Q68521141 | ||
| The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes | Q70068345 | ||
| Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis | Q70806623 | ||
| Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients | Q71677727 | ||
| Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study | Q73052317 | ||
| Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM | Q73307918 | ||
| Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin | Q77200327 | ||
| Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study | Q77318021 | ||
| Metformin added to insulin therapy in poorly controlled type 2 diabetes | Q77761970 | ||
| Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes | Q78044125 | ||
| Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial | Q78069268 | ||
| Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up | Q95721594 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation | Q29547453 | ||
| Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus | Q29616284 | ||
| Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group | Q29617736 | ||
| The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials | Q29619671 | ||
| What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes | Q30452941 | ||
| Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study | Q30598702 | ||
| Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group | Q31976463 | ||
| Pharmacologic therapy for type 2 diabetes mellitus | Q33716414 | ||
| Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial | Q33844615 | ||
| Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease | Q33872281 | ||
| Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. | Q33965301 | ||
| Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study | Q34452266 | ||
| How study design affects outcomes in comparisons of therapy. I: Medical | Q34530105 | ||
| Identifying relevant studies for systematic reviews | Q36888457 | ||
| The diabetes prevention program and its global implications | Q36920518 | ||
| The insulin-sparing effect of metformin in insulin-treated diabetic patients | Q40927900 | ||
| The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. A drug interaction study | Q41588331 | ||
| A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients | Q41704965 | ||
| Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. | Q51586579 | ||
| The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. | Q51592429 | ||
| Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. | Q51592594 | ||
| Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. | Q51593626 | ||
| The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. | Q51599034 | ||
| Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. | Q51602443 | ||
| Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. | Q51611207 | ||
| Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. | Q51616810 | ||
| A comparison of metformin versus guar in combination with sulphonylureas in the treatment of non insulin dependent diabetes. | Q51620671 | ||
| The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes. | Q51621526 | ||
| The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. | Q51622328 | ||
| A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes. | Q51626978 | ||
| Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. | Q51628832 | ||
| The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. | Q52869960 | ||
| Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. | Q53980492 | ||
| UK's diagnostic criteria for diabetes are different from US's | Q41892468 | ||
| Insulin Receptor Binding to Monocytes, Insulin Secretion, and Glucose Tolerance Following Metformin Treatment: Results of a Double-Blind Cross-Over Study in Type II Diabetics | Q42455201 | ||
| Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus | Q42491638 | ||
| The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial | Q42648581 | ||
| Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study | Q42685628 | ||
| Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial | Q42688840 | ||
| The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus | Q43546809 | ||
| Improved endothelial function with metformin in type 2 diabetes mellitus | Q43573534 | ||
| The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes | Q43618978 | ||
| Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients | Q43778450 | ||
| Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. | Q43795772 | ||
| Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects | Q43833535 | ||
| Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial | Q43843247 | ||
| Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles | Q43945425 | ||
| Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. | Q44016357 | ||
| Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin | Q44082233 | ||
| Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. | Q44198028 | ||
| Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes | Q44229910 | ||
| Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes | Q44230947 | ||
| Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects | Q44231018 | ||
| The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients | Q44249588 | ||
| Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue | Q44304698 | ||
| Leptin and body fat in type 2 diabetes and monodrug therapy | Q44392857 | ||
| Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes | Q44393965 | ||
| Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients | Q44395054 | ||
| Insulin and sulphonylurea in the therapy of type 2 diabetes | Q44426267 | ||
| Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea | Q44507814 | ||
| Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study | Q44517908 | ||
| Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes | Q44547506 | ||
| Comparison of tolbutamide and metformin in elderly diabetic patients | Q44942743 | ||
| Comparison of combined therapies in treatment of secondary failure to glyburide | Q44979137 | ||
| Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus | Q47265873 | ||
| Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes | Q47292595 | ||
| Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. | Q51550632 | ||
| Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. | Q51551544 | ||
| Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. | Q51552517 | ||
| Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. | Q51554552 | ||
| Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. | Q51554580 | ||
| Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. | Q51558539 | ||
| A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. | Q51561877 | ||
| Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. | Q51563377 | ||
| Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable? | Q51565233 | ||
| Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. | Q51566428 | ||
| Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. | Q51568639 | ||
| The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. | Q51569984 | ||
| Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. | Q51571115 | ||
| Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. | Q51572280 | ||
| Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. | Q51580222 | ||
| A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. | Q51582451 | ||
| Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. | Q51586347 | ||
| P921 | main subject | type 2 diabetes | Q3025883 |
| metformin | Q19484 | ||
| P577 | publication date | 2015-09-30 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Metformin monotherapy for type 2 diabetes mellitus |
Search more.